Ovid Therapeutics Inc.

What they do

Ovid in-licenses and clinically develops small molecule candidates targeting neuronal hyperexcitation for epilepsies and psychoses. It describes five clinical-stage programs, two of which reached late-stage trials, focused on drug-resistant focal onset seizures, developmental and epileptic encephalopathies including tuberous sclerosis complex seizures and infantile spasms, psychosis associated with Parkinson's disease and Lewy body dementia, and schizophrenia. Lead assets include OV329, a next-generation GABA-aminotransferase inhibitor, and OV4071, an oral direct activator of KCC2. Several preclinical programs are planned for other psychoses and mood disorders.

Revenue drivers

• Collaboration, license and milestone revenue — Revenue is episodic and tied to partner payments rather than product sales; annual revenue was $392,000 in 2023, $566,000 in 2024 and $7.3 million in 2025, with the 2025 step-up coinciding with the March 2026 private placement and warrant activity.
• Royalty and milestone payments from out-licensed programs — The filings list royalty or milestone payments among forward-looking revenue sources; the company holds no marketed medicine, so any such receipts would be event-driven rather than recurring.
• Grant and other non-product income — Quarterly revenue is small and irregular, ranging from $0 in the March 2026 quarter to $733,000 in the June 2026 quarter, consistent with miscellaneous non-product receipts rather than commercial sales.

Recent performance

Full year 2025 revenue was $7.3 million against a net loss of $17.4 million, a narrower loss than the $26.4 million reported for 2024. Operating cash flow was negative $38.3 million in 2025, an improvement from negative $56.0 million in 2024. Quarterly revenue was $718,000 in the December 2025 quarter, $0 in the March 2026 quarter and $733,000 in the June 2026 quarter. As of June 30, 2026, total assets were $232.0 million, total liabilities $22.1 million and shareholders' equity $209.9 million, with cash and equivalents of $11.3 million. Historically, revenue peaked at $208.4 million in 2021 with net income of $122.8 million, reflecting a one-time collaboration event rather than ongoing product sales.

Strategy

Ovid's near-term strategy is clinical advancement of small molecule medicines for specific epilepsies and psychoses arising from excitatory/inhibitory imbalance. In March 2026 it reported favorable 7 mg single and multiple ascending dose results for OV329 and said it plans a Phase 2 trial in focal onset seizures plus an open-label proof-of-concept study. It is expanding OV329 into tuberous sclerosis complex seizures and infantile spasms, funded by a private placement expected to yield $60.0 million in gross proceeds. For OV4071, HREC approval and Australian TGA clinical trial notification acknowledgement allow initiation of a Phase 1 trial and triggered a 30-day exercise period for outstanding Series A Warrants. The company states it intends to become a fully integrated neurotherapeutics company with multiple clinical-stage programs and commercial medicines.

Risks

• Need for additional capital — The company states it will require additional capital to finance operations and that failure to raise it when needed would force delays, limits or termination of drug development efforts.
• Continued operating losses — Ovid expects to continue incurring substantial operating losses for the foreseeable future and may never achieve or maintain profitability, with a net loss of $17.4 million in 2025 and negative operating cash flow every year from 2022 through 2025.
• Clinical development and regulatory uncertainty — No Ovid candidate is approved, and its programs depend on trial outcomes and regulatory filings for OV329, OV4071 and the remaining pipeline, including the planned OV329 Phase 2 trial and OV4071 Phase 1 trial.
• Dilution from financing — The company notes it may sell additional equity or debt securities, which could dilute stockholders and impose restrictions on the business; the March 2026 financing included a $60.0 million private placement and an unregistered sale of equity.

Outlook

Management points to a cadence of near-term clinical milestones, including a planned OV329 Phase 2 trial in focal onset seizures and an open-label proof-of-concept study, plus expansion of OV329 into tuberous sclerosis complex seizures and infantile spasms. OV4071 is expected to enter the clinic following HREC approval and TGA clinical trial notification acknowledgement. The company reported $90.4 million in cash, cash equivalents and marketable securities as of December 31, 2025, which it says is expected to fund key studies for OV329 and OV4071 and operations into late 2028, with exercise of outstanding warrants potentially extending the runway into 2029. It hosted a KCC2-focused R&D Day on April 14, 2026.